July 7, 2019  |  

Feasibility of real time next generation sequencing of cancer genes linked to drug response: results from a clinical trial.

Authors: Tran, Ben and Brown, Andrew M K and Bedard, Philippe L and Winquist, Eric and Goss, Glenwood D and Hotte, Sebastien J and Welch, Stephen A and Hirte, Hal W and Zhang, Tong and Stein, Lincoln D and Ferretti, Vincent and Watt, Stuart and Jiao, Wei and Ng, Karen and Ghai, Sangeet and Shaw, Patricia and Petrocelli, Teresa and Hudson, Thomas J and Neel, Benjamin G and Onetto, Nicole and Siu, Lillian L and McPherson, John D and Kamel-Reid, Suzanne and Dancey, Janet E

The successes of targeted drugs with companion predictive biomarkers and the technological advances in gene sequencing have generated enthusiasm for evaluating personalized cancer medicine strategies using genomic profiling. We assessed the feasibility of incorporating real-time analysis of somatic mutations within exons of 19 genes into patient management. Blood, tumor biopsy and archived tumor samples were collected from 50 patients recruited from four cancer centers. Samples were analyzed using three technologies: targeted exon sequencing using Pacific Biosciences PacBio RS, multiplex somatic mutation genotyping using Sequenom MassARRAY and Sanger sequencing. An expert panel reviewed results prior to reporting to clinicians. A clinical laboratory verified actionable mutations. Fifty patients were recruited. Nineteen actionable mutations were identified in 16 (32%) patients. Across technologies, results were in agreement in 100% of biopsy specimens and 95% of archival specimens. Profiling results from paired archival/biopsy specimens were concordant in 30/34 (88%) patients. We demonstrated that the use of next generation sequencing for real-time genomic profiling in advanced cancer patients is feasible. Additionally, actionable mutations identified in this study were relatively stable between archival and biopsy samples, implying that cancer mutations that are good predictors of drug response may remain constant across clinical stages. Copyright © 2012 UICC.

Journal: International journal of cancer
DOI: 10.1002/ijc.27817
Year: 2013

Read publication

Talk with an expert

If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.